Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to a recent article, “The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric disorders.” To achieve this, “Cybin plans on applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (‘ODT’) technology to the delivery of CYB003, Cybin’s novel deuterated tryptamine, as a potential therapy.”
To view the full article, visit https://ibn.fm/1oiwm
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.